Top Emerging Diabetes Care Companies - 2021
SAS Healthtech: Navigating Remote Patient Monitoring Solutions for The 21st Century

Top 10 Emerging Diabetes Care Companies - 2021

As the healthcare sector continues to follow the trails of technological progression, diabetes care is entering its next phase of evolution. One such advancement is connected continuous glucose monitoring (CGM) insulin pumps that enable patients to use the data from their CGM devices to suggest changes in dosing based on the situation. Similarly, another notable advancement is the FDA-approved smart insulin pens. These insulin pens are especially designed to busy or forgetful diabetic patients never miss a dosage. While smart insulin pens boasts many features like built-in wireless communication abilities and sensors to track insulin delivery, the cost of the pens are optimally priced for greater adoption.

At this juncture, many diabetes care solution providers are entering the domain with advanced and integrated offerings. To help the healthcare sector strengthen its operational capabilities and simultaneously enable growth in the industry, MedTech Outlook has compiled a list of the Top 10 Diabetes Care Solution Providers, and Top 10 Emerging Diabetes Care Companies. The list comprises prominent and emerging organizations in the industry that address issues pertinent to the diabetes care sector. Besides, the magazine also includes insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.

We present to you MedTech Outlook’s “Top 10 Emerging Diabetes Care Companies – 2021.”

    Top Emerging Diabetes Care Companies

    Prosenex
    Offers a portfolio of medical products and product designs is focused on addressing the unmet market needs of primary care physicians, podiatrists, neurologists, endocrinologists and occupational therapists in the screening of patients for peripheral neuropathy due to diabetes and other causes
    Ambrosia Systems
    Ambrosia Systems is a fast-growing medical technology company focused on building easy to use and affordable technology solutions for patients and caregivers around the world. We make devices which can read many different types of Near Field Communication (NFC) tags and transmit information to mobile devices or phones over a Bluetooth connection. Our products work equally well over iPhone, Android phone, iPod, Apple Watch or Android Watch. In the Diabetic space, our products work with Abbott’s NFC-based FreeStyle Libre and FreeStyle Libre Pro sensor to help patients continuously monitor their glucose levels on their mobile phone/watch every 5 minutes. They can do this without submitting to painful finger pricks or scanning the sensor with a Reader to access their glucose readings each time. This helps in the better treatment and patient care leading to a healthier lifestyle and better quality of life. Our product portfolio includes NightRider BluCon (an electronic transmitter for Abbott sensor readings), LinkBluCon mobile app for patients and Follow BluCon app for Caregivers, with many more innovations underway. The low-cost NightRider BluCon is currently in use in more than 100 countries across Asia, Europe, Australia, US and Canada resulting in significant cost savings in diabetic care
    GlySens
    GlySens is dedicated to advancing the care of individuals with diabetes through the development of a long term, implantable continuous glucose monitoring technology. Since the company’s inception in 1998, we have focused on designing and developing the world’s first truly long term, wireless, implantable, continuous glucose monitor, the Eclipse® ICGM® System. Our goal is to empower individuals with easy, at-a-glance, worry-free diabetes technologies that seamlessly deliver the information they need to optimize care, while freeing them to live life on their own terms
    Integrated Medical Sensors
    Integrated Medical Sensors (IMS) aims to provide a simple and effective solution for accurate and painless glucose monitoring for diabetes management. IMS is developing world's smallest and most affordable completely wireless glucose sensing solution that will allow diabetes patients to live a normal, productive and happy life. We have made an advanced, functional prototype and are working hard to get this technology in your hands as soon as possible
    Medality Medical
    Medality Medical, a privately funded (including an NIH grant) innovative medical technology company, is focused on reversing type 2 diabetes and associated obesity. Its patented technology enables the gentle extraction of excess mesenteric visceral fat found inside the abdomen. On February 5, 2019, the FDA approved Medality’s Investigational Device Exemption (“IDE”) application to undertake a human clinical trial for the extraction of excess mesenteric visceral fat to reverse T2D using its already FDA-cleared Targeted Cell Separation and Extraction device/system. FDA approval was based in part upon a landmark, National Institutes of Health (NIH) funded, pre-clinical non-human primate study. Reversal of insulin resistance, associated with type 2 diabetes, was achieved in all experimental baboons. In early 2018, these results were published in the peer-reviewed journal, Surgery for Obesity and Related Diseases, in an article entitled: Mesenteric visceral lipectomy using tissue liquefaction technology reverses insulin resistance and causes weight loss in baboons
    Mellitus
    Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child. We plan to commercialize our products through strategic partners as we expand indications to benefit all individuals with diabetes
    Metamodix
    Metamodix is dedicated to reducing the human and financial costs of metabolic diseases. Our first product, the EndoSleeve*, is designed to be a safer and more cost-effective treatment option for patients suffering from Type 2 Diabetes, Obesity, and NASH. Metamodix was founded with the goal of providing cost-effective therapy solutions to global unmet clinical needs. Our team is comprised of a set of experienced individuals with unique skills that is working to achieve this goal
    Movano
    Founded in 2018, Movano is a health-focused technology company creating simple, smart and personalized devices designed to help individuals on their health journey optimize for good health today and prevent and manage chronic diseases in the future. Movano’s technology is being developed to provide vital health information, including glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback in order to improve the quality of their life
    Qlibrium
    Qlibrium is committed to helping patients live life to the fullest by developing and innovating discreet and flexible drug delivery solutions. Qlibrium is developing a highly flexible platform technology for delivering injectable drugs into subcutaneous tissue with a wearable on-body delivery system that brings dramatic improvements over existing devices to both users and to pharmaceutical companies. Qlibrium, formerly known as Cam Med, began with a simple question: Why can’t a pump for injectable drugs work like an extension of the body? For patients with chronic conditions such as diabetes, Parkinson’s disease, hormone deficiencies, and blood disorders, as well as other conditions that require frequent injections of subcutaneous drugs, a better wearable pump translates into improved compliance and outcomes. Over the past several years, Qlibrium has been working to bring our vision of marked simplicity to reality with development of the QLib platform for prefilled delivery of drugs and biologics and QForma for diabetes patients. We have been issued several patents, with a strong portfolio of pending patents on key elements of our technology platform
    WaveForm Technologies
    WaveForm Technologies Inc. discovers and develops proprietary new technologies for diabetes care, including the first needle-free, CE approved continuous glucose monitoring system with a long wear time. We help people striving for better lives, build trust and confidence in managing diabetes, through a suite of innovative care solutions